INTRODUCTION
============

A vesicular rash of unilateral distribution limited to a single dermatome is characteristic of herpes zoster (HZ)[@B1]. HZ affecting two dermatomes or more occurs rarely (\<0.5%)[@B2]. In Korea, 19 cases of multidermatomal HZ, which affected two and more dermatomes, have been reported[@B3][@B4][@B5][@B6][@B7][@B8][@B9][@B10]. When two noncontiguous dermatomes are involved, if affected unilaterally, it is called HZ duplex unilateralis and if bilaterally, HZ duplex bilateralis[@B11]. Herein, we present two cases of zoster duplex unilateralis and a review of the previous literature.

CASE REPORT
===========

Case 1
------

A 66-year-old man presented with 3-day history of pain and erythematous grouped vesicles on his left scalp, forehead, trunk, and back (dermatome left \[Lt.\] V1, Lt. T8) ([Fig. 1](#F1){ref-type="fig"}). The patient appeared acutely ill; he has a 17-year history of hypertension and diabetes. He was also a chronic alcoholic, consuming 1\~2 bottles of alcohol per day. All results of laboratory studies, including a complete blood cell count and liver function tests, were negative or within normal limits, except for a high level of gamma glutamyl transferase. Polymerase chain reaction (PCR) from the blood and serologic tests for anti-varicella-zoster virus (VZV), immunoglobulin G (IgG) showed positive, but anti-VZV IgM was negative. We performed a punch biopsy from the vesicles on the Lt. scalp and Lt. trunk. Skin biopsy from the lesional skin showed intraepidermal blisters with characteristic eosinophilic intranuclear inclusion bodies and acantholitic multinucleated giant cells. Basal vacuolization, necrotic epidermal cells, and lymphocytic infiltration in the upper dermis were noted ([Fig. 2](#F2){ref-type="fig"}). He was diagnosed with HZ involving two noncontiguous unilateral dermatomes (Lt. V1, Lt. T8) and treated with oral administration of famcyclovir 750 mg/day for seven days; wet dressings were done four times weekly, until all the vesicles had crusted over. His scalp pain was relieved but pain in his trunk remained. He was transferred to anesthesiologist and a weekly nerve block was performed seven times during the four months since he first visited to our department (dermatology). His pain was improved but numbness of that area still exists.

Case 2
------

A 33-year-old woman presented with erythematous grouped vesicles and crust on her left forehead and neck ([Fig. 3](#F3){ref-type="fig"}). Her pain and skin lesion had started 3\~4 days and 1 day, respectively, before she visited our clinic. She had a history of atopic dermatitis (AD) when she was a child and her dyshidrosis began 5 years ago. Until now, tacrolimus ointment had been applied for her skin lesions. Laboratory studies, including a complete blood cell count and liver function tests, were done. All showed negative or within normal limits, except for a high eosinophil count and percentage (0.77×10^3^/µl, 12.7%). A serologic test and PCR from blood was done. Anti-VZV IgM was negative, but anti-VZV IgG was positive (1,341.0 mIU/ml). She was diagnosed with HZ involving two noncontiguous unilateral dermatomes (Lt. V1, Lt. C5). She was treated with oral administration of famcyclovir 750 mg/day for seven days and wet dressings were done three times. The skin lesions and pain subsided without complications.

DISCUSSION
==========

HZ is a relatively common disease (10% to 20% lifetime risk of HZ worldwide) and is characterized by several groups of painful vesicles with a characteristic distribution of unilateral dermatomes[@B1]. The incidence rate is slightly different in Korean literature, ranging from 0.38% to 2.84%[@B9][@B12][@B13][@B14]. Patients with malignancy, especially Hodgkin\'s disease and leukemia, are five times more likely to develop HZ than their age-matched counterparts. Other patients who also have a higher incidence of HZ include patients with deficient immune systems, such as individuals who were immunosuppressed for organ transplantation, by connective tissue disease, and by agents such as corticosteroids[@B1]. Noncontiguous HZ involving multiple dermatomes is very rare in both immunocompetent and immunocompromised patients[@B9][@B10]. The phenomenon of zoster occurring in two noncontiguous dermatomes has been referred to as HZ duplex unilateralis or bilateralis, depending on whether one half or both halves of the body are involved[@B5]. One article in 1986 reviewed the medical English literature over the last three decades and only seven cases of HZ occurring in noncontiguous dual dermatomes had been reported[@B15]. In 2012, one article reviewed HZ duplex and until then, only 23 cases had been reported[@B16].

In the Korean medical literature, we reviewed 17 cases of HZ duplex bilateralis or unilateralis ([Table 1](#T1){ref-type="table"})[@B3][@B4][@B5][@B6][@B7][@B8][@B9][@B10]. The clinical features of HZ duplex bilateralis or unilateralis in previous reports are as follows; the age of onset varied from four to 76 years of age, but it was more common with advanced age. The affected dermatomes varied from thoracic, trigeminal areas to the lumbar area. It has been reported that HZ duplex is more common among immunocompromised patients[@B4][@B5][@B15][@B16]. Castronovo and Nikkels[@B16] reviewed 23 cases of HZ duplex worldwide and the majority of the adult and pediatric cases had immunosuppression, leukemia, or lymphoma. In the Korean medical literature, more than half of the cases of HZ duplex bilateralis or unilateralis, patients also had acute leukemia, lymphoma, or malignancy such as lung cancer, rheumatoid arthritis, diabetes mellitus, hypertension, asthma, chronic obstructive lung disease, gastric ulcer, or human immunodeficiency virus infection. Among them, there were five cases of zoster duplex bilateralis or unilateralis in immunocompetent patients, and one of our cases was also an immunocompetent patient.

Reported cases involving two noncontiguous dermatomes showed reduced cell immunity more frequently than cases with only one dermatome[@B12]. Kim et al.[@B12] performed multi-cell medicated immunity testing in 88 patients and found differences in cell immunity depending on the number of dermatomes involved.

HZ duplex is the ultimate clinical proof that VZV remains latent in the majority of sensory dorsal root ganglia[@B16]. It is hypothesized that the highest viral genome load leads to clinical HZ. Concurrent VZV-specific immunoboosting induced by the HZ eruption probably prevents other eventual reactions from becoming expressed clinically. Only in cases of severe immunosuppression, VZV can be reactivated in multiple dorsal root ganglia and initiate multidermatomal HZ[@B16]. This might be due to secondary hematogenous infection[@B16]. A new VZV infection might occur hematogenously when VZV was already latent in more than two dermatomes[@B6].

In our cases, the male patient was aged and had a history of hypertension, diabetes, and chronic alcoholism. We speculate that he was in an immunocompromised state that led to defective cellular immune response, allowing the development of zoster duplex unilateralis. The female patient had a history of AD and dyshidrosis with a quiet long period of tacrolimus ointment application. Even tacrolimus ointment functions as an immunosuppressant; however, it had been reported that the use of topical tacrolimus for the treatment of AD is not associated with an increase in HZ as side effect[@B17]. But, it can be considered that dysfunction of cell-mediated immunity in AD patients can increase susceptibility to HZ. It is reported that patients who had previously been hospitalized in childhood because of severe AD had a significantly higher incidence of HZ than non-atopic controls[@B18].

Treatment for patients with HZ duplex was the same as the common treatment for HZ, which included an anti-viral agent, pain management, and care of the skin lesions. The skin lesions and pain subsided without complications in our female patient. However, the male patient had to be transferred to anesthesiologist due to postherpetic neuralgia. A weekly nerve block was performed seven times during four months. HZ duplex showed prognosis similar to that for HZ with only one nerve ganglion involved. It seems that HZ duplex is not a risk factor for poor prognosis and postherpetic neuralgia[@B16].
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![A 66-year-old man presented with erythematous grouped vesicles on his (A) left scalp, forehead (left \[Lt.\] V1), (B) trunk, and (C) back (Lt. T8).](ad-28-757-g001){#F1}

![(A) Skin biopsy from the skin lesion on the scalp shows intraepidermal blisters with characteristic eosinophilic intranuclear inclusion bodies and giant acantholytic multinucleated cells. Basal vacuolization, necrotic epidermal cells, and lymphocytic infiltration in the upper dermis are noted. (B) Skin biopsy from the skin lesion on the trunk also shows intraepidermal blisters with characteristic eosinophilic intranuclear inclusion bodies and acantholytic multinucleated giant cells (H&E, ×200).](ad-28-757-g002){#F2}

![A 33-year-old woman presented with erythematous grouped vesicles on her (A) forehead (left \[Lt.\] V1) and (B) neck (Lt. C5).](ad-28-757-g003){#F3}

###### Reported cases with multidermatomal herpes zoster

![](ad-28-757-i001)

  Reports              Age (yr)/sex   Location                                          Characteristic finding                            Treatment
  -------------------- -------------- ------------------------------------------------- ------------------------------------------------- ----------------------------
  Jin et al. (1990)    59/F           Lt. C5, Rt. T5                                    Lymphoma                                          \-
  Lee et al. (1994)    5/F            Lt. T2, Rt. T5                                    \-                                                PO ACV 400 mg/day×5 days
  No PHN                                                                                                                                  
  Jang et al. (1998)   65/M           Rt. V1, Lt. T4                                    \-                                                \-
  Kim et al. (1999)    46/F           Rt. L1\~2                                         AIDS                                              IV ACV 1,500 mg/day×6 days
  Bang et al. (2000)   68/M           Lt. V2, Lt. T10 Lt.                               DM, asthma                                        IV ACV 1,500 mg/day×7 days
  Jung et al. (2000)   59/F           V1\~2, Lt. L2                                     \-                                                IV ACV 750 mg/day×5 days
  Topical acyclovir                                                                                                                       
  Oh et al. (2001)     4/F            Lt. T4, Rt. T7\~8                                 \-                                                \-
  Jung et al. (2001)   65/M           Rt. V1, Lt. T4                                    \-                                                IV ACV 2,500 mg/day×5 days
  Shin et al. (2002)   22/F           Rt. T7, Lt. S3                                    Leukemia                                          PO FCV 750 mg/day×7 days,
  No PHN                                                                                                                                  
  Kim et al. (2004)    47/F           Rt. T4, Lt. L1                                    DM, HTN, RA                                       IV ACV 750 mg/day×5 days,
  No PHN                                                                                                                                  
  Park et al. (2005)   76/M           Rt. V1, Rt. T10, disseminated                     Gastric ulcer, COPD                               IV ACV 750 mg/day×5 days
  PHN                                                                                                                                     
  Ko et al. (2006)     54/F           Rt. T5\~7                                         Multiple myeloma (recur, Lt. T10 7 months ago)    PO FCV 750 mg/day×7 days
  Park et al. (2008)   71/F           Lt. V2, Lt. C4\~5, Rt. S2\~3, Lt. L1, Rt. T4\~5   Non-Hodgikin's lymphoma                           IV ACV 1,500 mg/day×7 days
  HTN, DM                                                                                                                                 
  Yoo et al. (2009)    49/F           Rt. T4, Lt. T4                                    Breast cancer                                     PO FCV 750 mg/day×7days
  No PHN                                                                                                                                  
  Shin et al. (2009)   67/F           Rt. L4\~5, Lt. T7\~8                              HTN, osteoporosis, lumbar spine compression Fx.   PO FCV 750 mg/day×7 days
  No PHN                                                                                                                                  
  Lim et al. (2009)    49/F           Rt. C7\~8, Lt. L2\~3                              Lung cancer                                       IV ACV 1,500 mg/day×7 days
  PHN                                                                                                                                     
  Ryu et al. (2010)    42/M           Rt. T4, Lt. T2                                    HIV                                               PO FCV 750 mg/day×7 days
  No PHN                                                                                                                                  
  Lee et al. (2011)    23/M           Rt. V1, Lt. V1                                    \-                                                IV ACV 750 mg/day×7 days
  No PHN                                                                                                                                  
  Yang et al. (2012)   65/F           Lt. C2\~5                                         \-                                                IV ACV 750 mg/day×5 days
  No PHN                                                                                                                                  

F: female, M: male, Lt.: left, Rt.: right, -: no data, PO: per oral, ACV: acyclovir, PHN: post-herpetic neuralgia, AIDS: acquired Immune deficiency syndrome, IV: intravenous, DM: diabetes mellitus, FCV: famciclovir, HTN: hypertension, RA: rheumatic arthritis, COPD: chronic obstructive pulmonary disease, Fx.: fracture, HIV: human immunodeficiency virus.
